Trials
2 active
6 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- A short strand of RNA that switches off one gene, so the body makes less of one protein.-siran: small interfering RNA WHO name stem
- How it’s given
- “Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection”In the company’s words, NCT04042402 on ClinicalTrials.gov
- Tested for
- Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease, Primary Hyperoxaluria Type 3 (PH3), Primary Hyperoxaluria Type 1, End Stage Renal Disease
- Main trialPhase 3
- “The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (\<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of DCR-PHXC in patients with PH.”In the company’s words, NCT04042402 on ClinicalTrials.gov
- Other names
- DCR-PHXC
Other drugs for Primary Hyperoxaluria Type 1 (PH1)
- StiripentolBiocodex · Phase 3
- YOLT-203YolTech Therapeutics Co., Ltd · Phase 2
- ABO-101Arbor Biotechnologies · Phase 1/2
Coming up2
- 1 Apr 2030Phase 3 trial completes · ClinicalTrials.gov
- 30 Dec 2031Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 1 Apr 2030 | Long Term Extension Study in Patients With Primary Hyperoxaluria | |
| Phase 2Recruiting | 30 Dec 2031 | Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD | |
| Phase 2Completed | 21 Jun 2021 | A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2 | |
| Phase 2Completed | 5 Feb 2025 | Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function | |
| Phase 1Completed | 19 Nov 2019 | Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria | |
| Phase 1Completed | 7 Sep 2021 | Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026